GAMMA Investing LLC Acquires 26,625 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

GAMMA Investing LLC raised its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 6,279.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,049 shares of the biopharmaceutical company’s stock after purchasing an additional 26,625 shares during the period. GAMMA Investing LLC’s holdings in Ultragenyx Pharmaceutical were worth $979,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. California State Teachers Retirement System raised its position in Ultragenyx Pharmaceutical by 0.3% during the fourth quarter. California State Teachers Retirement System now owns 78,051 shares of the biopharmaceutical company’s stock valued at $3,284,000 after purchasing an additional 268 shares in the last quarter. Van ECK Associates Corp increased its holdings in shares of Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 273 shares during the period. BOKF NA increased its holdings in shares of Ultragenyx Pharmaceutical by 5.0% in the fourth quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company’s stock worth $336,000 after buying an additional 382 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of Ultragenyx Pharmaceutical by 259.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 493 shares during the last quarter. Finally, Arizona State Retirement System grew its stake in shares of Ultragenyx Pharmaceutical by 2.4% in the fourth quarter. Arizona State Retirement System now owns 24,038 shares of the biopharmaceutical company’s stock worth $1,011,000 after purchasing an additional 568 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Wall Street Analysts Forecast Growth

RARE has been the topic of a number of research analyst reports. William Blair began coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They set an “outperform” rating and a $65.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Piper Sandler cut their price target on Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating for the company in a report on Monday, March 17th. Morgan Stanley upped their price objective on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an “overweight” rating in a research note on Friday, May 9th. Finally, JPMorgan Chase & Co. upped their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research note on Thursday, March 27th. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $88.77.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $37.11 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $29.59 and a 1 year high of $60.37. The stock’s 50 day simple moving average is $36.16 and its two-hundred day simple moving average is $39.90. The company has a market cap of $3.51 billion, a PE ratio of -5.85 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $139.29 million for the quarter, compared to analysts’ expectations of $145.98 million. During the same quarter last year, the company earned ($2.03) earnings per share. The company’s revenue for the quarter was up 28.0% on a year-over-year basis. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.